Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06519097 · ClinicalTrials.gov registry record · Phase 2
Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)
A Phase 2 study of IPMN, Pancreatic and Neoplasm of Pancreas, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
- 2
- Study locations
NCT06519097: Active Phase 2 study of IPMN, Pancreatic and Neoplasm of Pancreas, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT06519097 is a Phase 2 study of IPMN, Pancreatic and Neoplasm of Pancreas that is active but no longer recruiting, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06519097, a Phase 2 study of IPMN, Pancreatic and Neoplasm of Pancreas, is active but no longer recruiting, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled trial, investigating whether treatment with δ-tocotrienol (a.k.a. Delta-tocotrienol, abbreviated as DT3) will prevent the progression of Intraductal Papillary Mucinous Neoplasm (IPMN) of the pancreas.
Primary Outcome
IPMN progression free survival (iPFS) defined as duration from date of randomization to date of event (IPMN progression), pursuant to the international Kyoto guidelines and the European guidelines. IPMN will be considered as having progressed if any one or more of the following features occur: (i) increase in size of \> 1 mm; (ii) development of any worrisome feature (growth rate ≥ 5 mm/ 2 years, main pancreatic duct dilatation from 5-9 mm, acute pancreatitis caused by IPMN, enhancing mural no
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Vitamin E Delta Tocotrienol
Study Locations (2)
Florida
- Moffitt Cancer Center - Tampa
Nebraska
- University of Nebraska Medical Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2024-07-09 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What the registry record for NCT06519097 still lists
NCT06519097 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with IPMN, Pancreatic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06519097 reports a single indexed study location in Florida, Nebraska.
Frequently Asked Questions
What is clinical trial NCT06519097 about?
NCT06519097 is a clinical study titled "Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)". This is a randomized, double-blind, placebo-controlled trial, investigating whether treatment with δ-tocotrienol (a.k.a. Delta-tocotrienol, abbreviated as DT3) will prevent the progression of Intraductal Papillary Mucinous Neoplasm (IPMN) of the pancreas.
What is the current status of trial NCT06519097?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2024-07-09. Estimated completion is 2026-09.
What conditions does trial NCT06519097 study?
This clinical trial studies the following conditions: IPMN, Pancreatic, Neoplasm of Pancreas.
What interventions are being tested in trial NCT06519097?
The interventions under investigation include: Placebo (OTHER), Vitamin E Delta Tocotrienol (DRUG).
Who is sponsoring clinical trial NCT06519097?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06519097 being conducted?
This trial has 2 study locations across Florida, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IPMN, Pancreatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06519097's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI